Patients with BRCA 1/2 mutations not at increased risk for anthracycline-induced cardiotoxicity

the ONA take:

According to a new study presented last week at the 2014 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, researchers from Georgetown Lombardi Comprehensive Cancer Center and MedStar Heart & Vascular Institute in Washington, D.C., have found that patients with BRCA 1/2 gene mutations do not have an increased risk of anthracycline-induced cardiac toxicity compared with women who do not have the gene mutations.

The study was prompted by findings of preclinical studies that suggested otherwise. For the study, researchers enrolled 81 patients, 39 of whom were BRCA 1/2 carriers and 42 did not have the mutation. Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and metastatic disease were not included in the study. Patients with a history of hypertension were excluded as well.

To determine cardiotoxicity, patients had an echocardiogram following anthracycline therapy to determine left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS). Both are measurements to determine cardiac function.

Results showed that 91% of women had a normal LVEF  and 85% had a normal GLS, which were measured on average 45 months after therapy. Only one patient with BRCA 1/2 mutation had borderline reduced LVEF.

Patients with BRCA 1/2 mutations not at increased risk for anthracycline-induced cardiotoxicity
BRCA 1/2 gene mutations do not have an increased risk of anthracycline-induced cardiac toxicity.
Use of anthracycline-based chemotherapy, a common treatment for breast cancer, has negligible cardiac toxicity in women whose tumors have BRCA1/2 mutations -- despite preclinical evidence that such treatment can damage the heart. 
READ FULL ARTICLE From Medical News Today
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs